This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

6595 middle-aged men (age 45-64) with a mean cholesterol of 7.0 +/- 0.6 mmol were randomised to pravastatin 40 mg per day or placebo.

The average follow-up was 4.9 years.

Pravastatin altered serum lipids in the following manner:

  • serum cholesterol was reduced by 20%
  • serum LDL cholesterol was reduced by 26%

The relative risks in the pravastatin group reduced by:

  • 31% for coronary events
  • 31% for non-fatal myocardial infarction
  • 28% for death from definite coronary artery disease
  • reduction in total mortality by 22%

There was no significant excess in non-cardiovascular deaths in the pravastatin group.

Calculated - treating 1000 patients for 5 years - saves 7 deaths from CHD and 20 non-fatal MIs (1)

Primary prevention with pravastatin for 5 years continued to prevent coronary events in the following 10 years (2):

  • in this analysis, 5 years of treatment with pravastatin was associated with a significant reduction in coronary events for a subsequent 10 years in men with hypercholesterolemia who did not have a history of myocardial infarction


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page